According to the Consortium of Investigators of Modifiers of BRCA1/2, regarding the pathology of breast cancer with BRCA1/2 mutations [32], triple-negative breast cancer accounted for 69% of BRCA1 mutations and 16% of BRCA2 mutations, and the nuclear grades (grade 1, grade 2, and grade 3 [%]) were 3%, 20%, and 77% for BRCA1 mutations and 7%, 43%, and 50% for BRCA2 mutations, respectively. This evidence concerns the gene BRCA1 and breast carcinoma.